Gates Package — page 262
of 1375 pages · Bates Q2 2021
← p.261 p.263 → · this page in the original PDF · package
Merck
Remdesivir
and Antiviral/Immune__
Injection
Repurposed
Q1 2021
IFN-beta (Rebif)
Modulator
Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC)
Gilead & Other
Remdesivir and
Antiviral
Intravenous
N/A
Q3 2021
Hyperimmune
Intravenous
Immunoglobulin
(hIVIG)
Convalescent Plasma in Outpatients with COVID-19 (C3PO)
Other
Convalescent
Convalescent
Intravenous
N/A
Q4 2022
Plasma
Plasma
Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients (CONTAIN
COVID-19)
Other
Convalescent
Convalescent
Intravenous
N/A
Q2 2021
Plasma
Plasma
Passive Immunity Trial of Our Nation (PassItOn) Inpatient
Other
Convalescent
Convalescent
Intravenous
N/A
Plasma
Plasma
This page last reviewed on February 12, 2021
3/3
This is our OCR of the page, with running headers and footers removed. The
Committee's PDF
is authoritative; quote from it. Machine-readable, including the uncleaned
text: /api/page/gates/262
Records on this page
| Record | Date | Type | Pages |
|---|---|---|---|
| gates:exh:00155 | — | attachment | 262 |